205 related articles for article (PubMed ID: 25326793)
1. Association between miR34b/c polymorphism rs4938723 and cancer risk: a meta-analysis of 11 studies including 6169 cases and 6337 controls.
Wang X; Lu X; Fang Y; Chen H; Deng X; Peng C; Li H; Shen B
Med Sci Monit; 2014 Oct; 20():1977-82. PubMed ID: 25326793
[TBL] [Abstract][Full Text] [Related]
2. The genetic association between pri-miR-34b/c polymorphism (rs4938723 T > C) and susceptibility to cancers: evidence from published studies.
Li X; Wang L; Yu J; Xu J; Du J
Tumour Biol; 2014 Dec; 35(12):12525-34. PubMed ID: 25190019
[TBL] [Abstract][Full Text] [Related]
3. Association between miR-34b/c rs4938723 polymorphism and risk of cancer: An updated meta-analysis of 27 case-control studies.
Hashemi M; Moazeni-Roodi A; Bahari G; Taheri M; Ghavami S
J Cell Biochem; 2019 Mar; 120(3):3306-3314. PubMed ID: 30203457
[TBL] [Abstract][Full Text] [Related]
4. Pri-miR-34b/c rs4938723 Polymorphism Contributes to Coronary Artery Disease Susceptibility.
Cen J; Xiong Q; Yang X; Guo J; Xiong XD; Zhang A
Arch Med Res; 2019 May; 50(4):170-174. PubMed ID: 31499476
[TBL] [Abstract][Full Text] [Related]
5. Association between hsa-miR-34b/c rs4938723 T > C promoter polymorphism and cancer risk: a meta-analysis based on 6,036 cases and 6,204 controls.
Tao T; Chen S; Xu B; Liu C; Wang Y; Huang Y; Chen M
Chin J Cancer Res; 2014 Jun; 26(3):315-22. PubMed ID: 25035659
[TBL] [Abstract][Full Text] [Related]
6. Pri-miR-34b/c rs4938723 TC heterozygote is associated with increased cancer risks: evidence from published data.
Yi DH; Wang BG; Zhong XP; Liu H; Liu YF
Tumour Biol; 2014 Dec; 35(12):11967-75. PubMed ID: 25201061
[TBL] [Abstract][Full Text] [Related]
7. An updated meta-analysis of 23 case-control studies on the association between miR-34b/c polymorphism and cancer risk.
Li H; Diao S; Li J; Ma B; Yuan S
Oncotarget; 2017 Apr; 8(17):28888-28896. PubMed ID: 28415817
[TBL] [Abstract][Full Text] [Related]
8. MiR-34b/c rs4938723 Polymorphism Significantly Decreases the Risk of Digestive Tract Cancer: Meta-analysis.
Ji TX; Zhi C; Guo XG; Zhou Q; Wang GQ; Chen B; Ma FF
Asian Pac J Cancer Prev; 2015; 16(14):6099-104. PubMed ID: 26320502
[TBL] [Abstract][Full Text] [Related]
9. Pri-miR-34b/c rs4938723 polymorphism increased the risk of prostate cancer.
Hashemi M; Danesh H; Bizhani F; Narouie B; Sotoudeh M; Nouralizadeh A; Sharifiaghdas F; Bahari G; Taheri M
Cancer Biomark; 2017; 18(2):155-159. PubMed ID: 27983526
[TBL] [Abstract][Full Text] [Related]
10. Rs4938723 Polymorphism Is Associated with Susceptibility to Hepatocellular Carcinoma Risk and Is a Protective Factor in Leukemia, Colorectal, and Esophageal Cancer.
Xu B; Zhu Y; Tang Y; Zhang Z; Wen Q
Med Sci Monit; 2018 Oct; 24():7057-7071. PubMed ID: 30286050
[TBL] [Abstract][Full Text] [Related]
11. Association between a polymorphism in miR-34b/c and susceptibility to cancer--a meta-analysis.
Lin Z; Chen L; Song M; Shi KQ; Tang KF
Asian Pac J Cancer Prev; 2014; 15(17):7251-5. PubMed ID: 25227823
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the pri-miR-34b/c rs4938723 polymorphism and its association with breast cancer risk.
Sanaei S; Hashemi M; Rezaei M; Hashemi SM; Bahari G; Ghavami S
Biomed Rep; 2016 Jul; 5(1):125-129. PubMed ID: 27347415
[TBL] [Abstract][Full Text] [Related]
13. Association between rs4938723 functional polymorphism in the promoter region of miR-34b/c gene and cancer risk.
Liu Q; Yang G; Song XL; Wang Z; Shi G
Clin Res Hepatol Gastroenterol; 2015 Sep; 39(4):526-33. PubMed ID: 25475831
[TBL] [Abstract][Full Text] [Related]
14. Lack of association of MiR-34b/c polymorphism (rs4938723) with hepatocellular carcinoma: a meta-analysis.
Liang TJ; Liu HJ; Zhao XQ; Yu CH; Li CS
PLoS One; 2013; 8(7):e68588. PubMed ID: 23935875
[TBL] [Abstract][Full Text] [Related]
15. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with renal cell cancer risk in a Chinese population.
Zhang S; Qian J; Cao Q; Li P; Wang M; Wang J; Ju X; Meng X; Lu Q; Shao P; Zhang Z; Qin C; Yin C
Mutagenesis; 2014 Mar; 29(2):149-54. PubMed ID: 24503183
[TBL] [Abstract][Full Text] [Related]
16. Pri-miR-34b/c rs4938723 polymorphism is associated with a decreased risk of gastric cancer.
Pan XM; Sun RF; Li ZH; Guo XM; Qin HJ; Gao LB
Genet Test Mol Biomarkers; 2015 Apr; 19(4):198-202. PubMed ID: 25658980
[TBL] [Abstract][Full Text] [Related]
17. Combined analysis of pri-miR-34b/c rs4938723 and TP53 Arg72Pro with cervical cancer risk.
Yuan F; Sun R; Chen P; Liang Y; Ni S; Quan Y; Huang J; Zhang L; Gao L
Tumour Biol; 2016 May; 37(5):6267-73. PubMed ID: 26619844
[TBL] [Abstract][Full Text] [Related]
18. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma.
Xu Y; Liu L; Liu J; Zhang Y; Zhu J; Chen J; Liu S; Liu Z; Shi H; Shen H; Hu Z
Int J Cancer; 2011 Jan; 128(2):412-7. PubMed ID: 20309940
[TBL] [Abstract][Full Text] [Related]
19. pri-miR-34b/c rs4938723 polymorphism is associated with hepatocellular carcinoma risk: a case-control study in a Chinese population.
Liu CJ; Ma XW; Zhang XJ; Shen SQ
Int J Mol Epidemiol Genet; 2017; 8(1):1-7. PubMed ID: 28337312
[TBL] [Abstract][Full Text] [Related]
20. Association of TP53 rs1042522 C>G and miR-34b/c rs4938723 T>C polymorphisms with hepatoblastoma susceptibility: A seven-center case-control study.
Liu P; Zhuo ZJ; Zhu J; Yang Z; Xin Y; Li S; Li L; Li Y; Wang H; He J
J Gene Med; 2020 Jul; 22(7):e3182. PubMed ID: 32166848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
